Aclaris Therapeutics Inc Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Aclaris Therapeutics Inc (NASDAQ: ACRS) yesterday and set a price target of $50. The company’s shares opened today at $20.21.

Chen wrote:

“We rate ACRS as 12-month price target of $50. We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. This could come from positive news flow for each of Aclaris’ three key programs over the next 12-18 months. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12- month price target of $50.”

According to TipRanks.com, Chen has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.5% and a 40.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Spero Therapeutics Inc, and Revance Therapeutics.

Aclaris Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $50.

Based on Aclaris Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $30.23 million. In comparison, last year the company had a GAAP net loss of $12.56 million.

Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACRS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address unmet needs in medical and aesthetic dermatology and immunology. It operates thrpough Dermatology Therapeutics and Contract Research segments.